Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Navitas Semiconductor Corporation Common Stock (NVTS) vs Organon & Co. Common Stock (OGN) Price & Performance

Navitas Semiconductor Corporation Common StockTrade
Organon & Co. Common StockTrade

Price performance (Past 24H)

Key statistics

Navitas Semiconductor Corporation Common Stock vs Organon & Co. Common Stock — how do they compare? Navitas Semiconductor Corporation Common Stock trades at $9.03 (market cap $2.63B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Navitas Semiconductor Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Navitas Semiconductor Corporation Common Stock for 3 Days and Organon & Co. Common Stock for 0 Days on average.

NVTSOGN
Market Cap
$2.63B$3.62B
Volume
20,633,0692,892,999
Sector
TechnologyHealth
52-Week High
$31.79$13.81
52-Week Low
$7.14$5.70
Typical Hold Time
3 Days0 Days
Enterprise Value
$2.07B$11.04B
Dividend Yield
—0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Navitas Semiconductor Corporation Common Stock

Navitas Semiconductor (NVTS) trades at $10.45, up 4.6% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal overall, with moving averages indicating selling pressure, but oscillators suggest some bullish momentum. Fundamentally, the company is in a growth investment phase, reporting negative net income margins and significant cash burn from operations, offset by strong financing inflows. Recent news highlights strategic collaborations with NVIDIA and Microchip for AI data center power solutions and a U.S. Army contract for silicon carbide chip development, positioning NVTS in high-growth power semiconductor markets.

The outlook for NVTS hinges on execution in the AI and defense power semiconductor segments, with a consensus price target of $16.65 implying substantial upside. However, high valuation multiples, persistent losses, and competitive intensity pose significant risks. Investors should weigh the company's promising market positioning against its current lack of profitability and the capital-intensive nature of its expansion.

Organon & Co. Common Stock

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVTS
100% Buy0% Sell
Avg holding period · 3 Days
OGN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Navitas Semiconductor Corporation Common Stock

Navitas Semiconductor designs and markets gallium nitride and silicon carbide power semiconductors. Its products are used in power conversion and charging for data centers, energy infrastructure, and industrial applications.

Read more on NVTS →

About Organon & Co. Common Stock

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.

Read more on OGN →